
  
    
      
        Background_NNP
        A_DT plethora_NN of_IN circumstantial_JJ evidence_NN implicates_NNS
        downregulation_NN of_IN the_DT cyclin-dependent_JJ kinase_NN (_( CDK_NNP )_)
        inhibitor_NN p_NN 27_CD in_IN prostate_NN cancer_NN ._. While_IN greater_JJR than_IN 85_CD %_NN of_IN
        terminally_RB differentiated_JJ secretory_NN cells_NNS in_IN normal_JJ human_JJ
        prostate_NN display_NN strong_JJ nuclear_JJ staining_VBG for_IN p_NN 27_CD ,_, all_DT cases_NNS
        of_IN high-grade_JJ prostatic_JJ intraepithelial_NN neoplasia_NN ,_, invasive_JJ
        carcinoma_NN ,_, and_CC pelvic_JJ lymph_NN node_NN metastases_NNS studied_VBN by_IN
        DeMarzo_NNP 
        et_CC al_NN ._. showed_VBD down-regulation_JJ of_IN p_NN 27_CD
        [_NN 1_CD ]_NN ._. In_IN addition_NN ,_, low_JJ p_NN 27_CD expression_NN correlates_NNS with_IN
        higher_JJR mean_NN Gleason_NNP scores_NNS ,_, a_DT number_NN of_IN prognostic_JJ
        morphological_JJ features_NNS ,_, and_CC decreased_VBD survival_NN [_NN 2_CD 3_CD 4_CD ]_NN ._.
        Thus_RB ,_, p_NN 27_CD may_MD be_VB a_DT prostate_NN tumor_NN suppressor_NN ._.
        In_IN support_NN of_IN this_DT notion_NN ,_, the_DT p_NN 27_CD protein_NN has_VBZ been_VBN
        identified_VBN as_IN a_DT target_NN of_IN viral_JJ oncoproteins_NNS [_NN 5_CD 6_CD ]_NN ._.
        However_RB ,_, unlike_IN traditional_JJ tumor_NN suppressors_NNS ,_, the_DT p_NN 27_CD gene_NN
        rarely_RB shows_VBZ homozygous_JJ inactivation_NN in_IN cancer_NN cells_NNS [_NN 7_CD 8_CD
        9_CD ]_NN ,_, a_DT finding_VBG that_IN points_NNS towards_IN alternative_JJ mechanisms_NNS
        of_IN p_NN 27_CD inactivation_NN ._.
        p_NN 27_CD specifically_RB inhibits_NNS CDKs_NNP ,_, which_WDT mediate_VB entry_NN into_IN
        S_NNP phase_NN [_NN 10_CD 11_CD ]_NN ._. The_DT level_NN of_IN p_NN 27_CD is_VBZ higher_JJR in_IN quiescent_JJ
        than_IN in_IN proliferating_VBG cells_NNS ,_, and_CC this_DT increase_NN in_IN p_NN 27_CD
        abundance_NN is_VBZ required_VBN for_IN an_DT effective_JJ cell_NN cycle_NN exit_NN [_NN 12_CD
        ]_NN ._. The_DT cell_NN cycle-dependent_JJ variations_NNS in_IN p_NN 27_CD levels_NNS are_VBP
        not_RB reflected_VBN by_IN similar_JJ changes_NNS in_IN p_NN 27_CD mRNA_NN [_NN 13_CD ]_NN ._. Many_JJ
        aggressive_JJ prostate_NN cancers_NNS display_NN decreased_VBD p_NN 27_CD protein_NN
        levels_NNS in_IN the_DT presence_NN of_IN high_JJ p_NN 27_CD mRNA_NN [_NN 14_CD ]_NN ,_, suggesting_VBG
        that_DT p_NN 27_CD depletion_NN may_MD result_VB from_IN ectopic_JJ proteolysis_NNS ._. In_IN
        fact_NN ,_, p_NN 27_CD depletion_NN in_IN several_JJ cancers_NNS was_VBD shown_VBN to_TO result_VB
        from_IN increased_VBN proteolysis_NNS via_IN the_DT ubiquitin_NN /_NN proteasome_NN
        system_NN [_NN 15_CD 16_CD 17_CD 18_CD ]_NN ._.
        This_DT system_NN employs_VBZ a_DT cascade_NN of_IN enzymatic_JJ reactions_NNS
        that_WDT covalently_RB attach_VB a_DT ubiquitin_NN chain_NN to_TO substrate_NN
        proteins_NNS ,_, thereby_RB targeting_VBG them_PRP to_TO the_DT proteasome_NN [_NN 19_CD ]_NN ._.
        The_DT ubiquitin_NN transfer_NN reaction_NN involves_VBZ three_CD enzymes_NNS :_: E_NNP 1_CD ,_,
        which_WDT mediates_NNS the_DT ATP-dependent_NNP activation_NN of_IN ubiquitin_NN ,_,
        and_CC E_NNP 2_CD ,_, or_CC ubiquitin_NN conjugating_VBG enzyme_NN (_( UBC_NNP )_) ,_, which_WDT ,_,
        together_RB with_IN an_DT E_NNP 3_CD ubiquitin_NN ligase_NN ,_, transfers_NNS ubiquitin_NN
        to_TO the_DT target_NN protein_NN ._.
        Biochemical_NNP studies_NNS identified_VBD SCF_NNP SKP_NNP 2_CD ,_, an_DT E_NNP 3_CD that_IN
        mediates_NNS p_NN 27_CD ubiquitylation_NN 
        in_IN vitro_NN [_NN 20_CD 21_CD ]_NN ._. This_DT complex_JJ
        consists_VBZ of_IN at_IN least_JJS four_CD proteins_NNS :_: SKP_NNP 1_CD ,_, CUL_NNP 1_CD ,_, HRT_NNP 1_CD
        (_( =_SYM RBX_NNP 1_CD /_NN ROC_NNP 1_LS )_) ,_, and_CC SKP_NNP 2_CD ._. SKP_NNP 2_CD contains_VBZ a_DT so-called_JJ F-_NNP box_NN ,_,
        which_WDT mediates_NNS binding_JJ to_TO SKP_NNP 1_CD ,_, and_CC C-_NNP terminal_NN leucine-rich_JJ
        repeats_NNS that_WDT recognize_VBP p_NN 27_CD ._. CUL_NNP 1_CD ,_, in_IN turn_NN binds_NNS to_TO SKP_NNP 1_CD ,_,
        and_CC together_RB with_IN HRT_NNP 1_CD ,_, mediates_NNS the_DT interaction_NN with_IN the_DT
        ubiquitin-conjugating_JJ enzyme_NN CDC_NNP 34_CD /_NN UBC_NNP 3_CD ._. CKS_NNP 1_CD ,_, a_DT small_JJ
        protein_NN that_IN associates_NNS with_IN CDKs_NNP and_CC greatly_RB stimulates_NNS
        p_NN 27_CD ubiquitylation_NN ,_, was_VBD recently_RB identified_VBN as_IN a_DT forth_RB SCF_NNP
        SKP_NNP 2_CD component_NN [_NN 22_CD 23_CD ]_NN ._.
        Two_CD rate-limiting_JJ steps_NNS for_IN p_NN 27_CD ubiquitylation_NN were_VBD
        defined_VBN :_: (_( 1_CD ._. )_) phosphorylation_NN of_IN p_NN 27_CD by_IN CDK_NNP 2_CD at_IN threonine_NN
        187_CD [_NN 24_CD 25_CD 26_CD ]_NN ,_, and_CC (_( 2_CD ._. )_) binding_JJ of_IN phosphorylated_JJ p_NN 27_CD
        to_TO SKP_NNP 2_CD [_NN 20_CD 21_CD ]_NN ._. SKP_NNP 2_CD is_VBZ down-regulated_JJ in_IN resting_VBG cells_NNS
        with_IN stable_JJ p_NN 27_CD ,_, but_CC strongly_RB up-regulated_JJ in_IN cells_NNS ,_, which_WDT
        progress_NN into_IN S_NNP phase_NN [_NN 27_CD 28_CD ]_NN ._. In_IN some_DT tissue_NN culture_NN
        cells_NNS ,_, overexpression_NN of_IN SKP_NNP 2_CD is_VBZ sufficient_JJ to_TO induce_VB p_NN 27_CD
        degradation_NN and_CC S_NNP phase_NN entry_NN [_NN 29_CD 30_CD 31_CD 32_CD ]_NN ,_, and_CC can_MD
        cooperate_VB with_IN 
        ras_NNS in_IN transformation_NN [_NN 33_CD 34_CD ]_NN ._.
        Significantly_RB ,_, overexpression_NN of_IN SKP_NNP 2_CD has_VBZ been_VBN observed_VBN in_IN
        many_JJ cancer_NN cell_NN lines_NNS [_NN 28_CD 35_CD ]_NN as_RB well_RB as_IN in_IN primary_JJ
        cancer_NN specimens_NNS and_CC many_JJ of_IN these_DT tumors_NNS also_RB display_VBP
        down-regulation_JJ of_IN p_NN 27_CD [_NN 33_CD 36_CD 37_CD 38_CD ]_NN ._.
        Here_RB ,_, we_PRP used_VBD the_DT androgen-sensitive_JJ human_JJ prostate_NN
        cancer_NN cell_NN line_NN LNCaP_NNP [_NN 39_CD ]_NN as_IN a_DT model_NN system_NN to_TO address_VB
        the_DT role_NN of_IN SKP_NNP 2_CD in_IN androgen-mediated_JJ cell_NN cycle_NN control_NN ._.
        This_DT cell_NN line_NN undergoes_NNS reversible_JJ G_NNP 1_CD arrest_NN in_IN response_NN
        to_TO androgens_NNS [_NN 40_CD 41_CD 42_CD 43_CD 44_CD ]_NN ._. The_DT G_NNP 1_CD arrest_NN is_VBZ
        accompanied_VBN by_IN p_NN 27_CD upregulation_NN [_NN 42_CD 43_CD 45_CD ]_NN ,_, however_RB the_DT
        pathway_NN leading_VBG to_TO p_NN 27_CD upregulation_NN is_VBZ unknown_JJ ._. We_PRP show_VBP
        that_IN androgen-induced_JJ p_NN 27_CD upregulation_NN is_VBZ paralleled_JJ by_IN p_NN 27_CD
        stabilization_NN and_CC SKP_NNP 2_CD downregulation_NN ._. SKP_NNP 2_CD overexpression_NN
        is_VBZ sufficient_JJ to_TO overcome_VB androgen-mediated_JJ p_NN 27_CD
        accumulation_NN ,_, indicating_VBG that_IN it_PRP is_VBZ a_DT major_JJ mediator_NN of_IN
        androgen-mediated_JJ cell_NN cycle_NN control_NN ._.
      
      
        Results_NNS
        
          Androgen-induced_NNP G_NNP 1_CD arrest_NN correlates_NNS with_IN
          inhibition_NN of_IN cyclin_NN E_NNP kinase_NN activity_NN
          Consistent_NNP with_IN our_PRP$ previous_JJ studies_NNS ,_, the_DT synthetic_JJ
          androgen_NN 7_CD α-_NN 17_CD α-dimethyl-_JJ 19_CD -_: nortestosterone_NN (_( mibolerone_NN ,_,
          MIB_NNP )_) inhibits_NNS the_DT proliferation_NN and_CC suppresses_NNS the_DT
          transformed_VBN phenotype_NN of_IN LNCaP_NNP cells_NNS (_( [_NN 46_CD ]_NN and_CC Fig_NNP ._.
          1_LS A_DT )_) ._. No_DT cytotoxic_JJ or_CC apoptosis-inducing_JJ activity_NN was_VBD
          associated_VBN with_IN this_DT growth_NN inhibition_NN (_( [_NN 46_CD ]_NN ,_, and_CC
          data_NNS not_RB shown_VBN )_) ._. To_TO determine_VB whether_IN MIB_NNP caused_VBD arrest_NN
          in_IN a_DT particular_JJ phase_NN of_IN the_DT cell_NN cycle_NN ,_, MIB_NNP treated_VBD
          cells_NNS were_VBD examined_VBN by_IN flow_NN cytometry_NN ._. MIB_NNP induced_VBD a_DT
          time-dependent_JJ accumulation_NN of_IN cells_NNS in_IN G_NNP 1_CD at_IN the_DT expense_NN
          of_IN both_DT S_NNP and_CC G_NNP 2_CD /_NN M_NNP phases_NNS (_( Fig_NNP ._. 1_LS B_NNP )_) ._. Consistent_NNP with_IN G_NNP 1_CD
          arrest_NN ,_, MIB_NNP induced_VBD inhibition_NN of_IN cyclin_NN E-_NNP associated_VBN H_NNP 1_CD
          kinase_NN activity_NN (_( Fig_NNP ._. 1_LS C_NNP )_) ._. This_DT inhibition_NN correlated_JJ
          with_IN increased_VBN recovery_NN of_IN the_DT CDK_NNP 2_CD inhibitor_NN p_NN 27_CD in_IN
          cyclin_NN E_NNP immunocomplexes_NNS isolated_VBN from_IN MIB-treated_NNP LNCaP_NNP
          cells_NNS (_( Fig_NNP ._. 1_LS D_NNP )_) ._. Similar_JJ finding_NN were_VBD previously_RB obtained_VBN
          with_IN the_DT synthetic_JJ androgen_NN R_NN 1881_CD and_CC the_DT natural_JJ
          androgen_NN dihydrotestosterone_NN (_( DHT_NNP )_) [_NN 42_CD 43_CD ]_NN ._. The_DT latter_JJ
          study_NN also_RB showed_VBD that_DT p_NN 27_CD is_VBZ quantitatively_RB bound_VBN to_TO
          cyclin_NN E_NNP complexes_NNS in_IN DHT-treated_NNP cells_NNS ,_, indicating_VBG that_DT
          p_NN 27_CD upregulation_NN was_VBD sufficient_JJ to_TO saturate_VB and_CC inhibit_VB
          cyclinE_NN /_NN CDK_NNP 2_CD complexes_NNS [_NN 43_CD ]_NN ._.
        
        
          MIB-induced_NNP cell_NN cycle_NN arrest_NN and_CC CDK_NNP 2_CD inhibition_NN
          coincide_VB with_IN upregulation_NN of_IN p_NN 27_CD and_CC downregulation_NN of_IN
          SKP_NNP 2_CD
          Consistent_NNP with_IN increased_VBN recovery_NN of_IN p_NN 27_CD in_IN cyclin_NN E_NNP
          complexes_NNS ,_, MIB_NNP caused_VBD a_DT concentration_NN and_CC time-dependent_JJ
          increase_NN in_IN steady-state_JJ p_NN 27_CD protein_NN levels_NNS (_( Fig_NNP ._. 2_LS A_DT ,_, 2_CD B_NNP )_) ._.
          This_DT increase_NN was_VBD reversible_JJ ,_, as_IN p_NN 27_CD levels_NNS were_VBD
          gradually_RB restored_VBN to_TO near_IN control_NN levels_NNS after_IN removal_NN
          of_IN MIB_NNP and_CC addition_NN of_IN a_DT 500_CD -_: fold_VB molar_NN excess_NN of_IN the_DT
          antiandrogen_NN cyproterone_NN acetate_NN (_( CA_NNP )_) (_( Fig_NNP ._. 2_LS Cand_NNP 2_CD D_NNP )_) ._.
          Simultaneous_NNP administration_NN of_IN MIB_NNP and_CC CA_NNP partially_RB
          prevented_VBD p_NN 27_CD accumulation_NN ,_, indicating_VBG that_IN it_PRP was_VBD
          mediated_JJ by_IN the_DT androgen_NN receptor_NN (_( AR_NNP )_) (_( Fig_NNP ._. 2_LS D_NNP )_) ._.
          Since_IN the_DT level_NN of_IN SKP_NNP 2_CD is_VBZ a_DT rate-limiting_JJ determinant_NN
          of_IN p_NN 27_CD levels_NNS [_NN 20_CD 21_CD 29_CD ]_NN ,_, we_PRP examined_VBD the_DT effect_NN of_IN
          MIB_NNP on_IN SKP_NNP 2_CD protein_NN levels_NNS ._. SKP_NNP 2_CD levels_NNS were_VBD
          down-regulated_JJ nearly_RB four-fold_RB by_IN MIB_NNP at_IN concentrations_NNS
          and_CC with_IN kinetics_NNS that_WDT closely_RB paralleled_JJ p_NN 27_CD
          accumulation_NN (_( Fig_NNP ._. 2_LS A_DT ,_, 2_CD B_NNP )_) ._. In_IN addition_NN ,_, downregulation_NN of_IN
          RB_NNP 1_CD and_CC accumulation_NN in_IN the_DT underphosphorylated_JJ form_NN
          paralleled_JJ SKP_NNP 2_CD down-regulation_JJ (_( Fig_NNP ._. 2_LS A_DT )_) ._. In_IN contrast_NN ,_,
          only_RB minor_JJ changes_NNS were_VBD detected_VBN in_IN the_DT expression_NN of_IN the_DT
          SKP_NNP 2_CD -_: associated_VBN SCF_NNP SKP_NNP 2_CD subunits_NNS HRT_NNP 1_CD ,_, CUL_NNP 1_CD ,_, and_CC SKP_NNP 1_CD
          (_( Fig_NNP ._. 2_LS A_DT )_) ._. MIB-dependent_NNP SKP_NNP 2_CD down-regulation_JJ was_VBD
          efficiently_RB counteracted_VBN by_IN CA_NNP (_( Fig_NNP ._. 2_LS Cand_NNP 2_CD D_NNP )_) ,_, again_RB
          indicating_VBG an_DT involvement_NN of_IN the_DT AR_NNP ._. Cyclin_NNP A_DT ,_, but_CC not_RB
          cyclin_NN E_NNP levels_NNS were_VBD also_RB suppressed_VBN by_IN MIB_NNP in_IN an_DT
          AR-dependent_NNP manner_NN ,_, while_IN the_DT levels_NNS of_IN the_DT
          COP_NNP 9_CD /_NN signalosome_NN subunit_NN CSN_NNP 5_CD /_NN JAB_NNP 1_CD and_CC tubulin_NN remained_VBD
          constant_JJ (_( Fig_NNP ._. 2_LS D_NNP )_) ._. Finally_RB ,_, consistent_JJ with_IN SKP_NNP 2_CD and_CC p_NN 27_CD
          being_VBG integral_JJ components_NNS of_IN androgen-mediated_JJ growth_NN
          control_NN of_IN LNCaP_NNP cells_NNS ,_, CA_NNP also_RB efficiently_RB reversed_VBD the_DT
          MIB-induced_NNP G_NNP 1_CD cell_NN cycle_NN arrest_NN (_( Fig_NNP ._. 2_LS E_NNP )_) ._.
          To_TO confirm_VB the_DT effect_NN of_IN MIB_NNP on_IN p_NN 27_CD and_CC SKP_NNP 2_CD at_IN the_DT
          level_NN of_IN individual_JJ cells_NNS ,_, we_PRP performed_VBD
          immunofluorescence_NN staining_VBG ._. In_IN untreated_JJ controls_NNS ,_, most_JJS
          cells_NNS displayed_VBD strong_JJ staining_VBG for_IN SKP_NNP 2_CD with_IN few_JJ cells_NNS
          positive_JJ for_IN p_NN 27_CD (_( Fig_NNP ._. 2_LS F_NN )_) ._. The_DT nuclear_JJ staining_VBG patterns_NNS
          of_IN SKP_NNP 2_CD and_CC p_NN 27_CD appeared_VBD mutually_RB exclusive_JJ ._. (_( Fig_NNP ._. 2_LS F_NN )_) ._.
          In_IN contrast_NN ,_, the_DT majority_NN of_IN MIB-treated_NNP cells_NNS showed_VBD
          strong_JJ p_NN 27_CD expression_NN ,_, while_IN only_RB few_JJ cells_NNS were_VBD positive_JJ
          for_IN SKP_NNP 2_CD ._.
        
        
          MIB-induced_NNP p_NN 27_CD upregulation_NN correlates_NNS with_IN
          increased_VBN p_NN 27_CD protein_NN stability_NN and_CC decreased_VBD
          ubiquitylation_NN
          Northern_JJ blot_NN analysis_NN revealed_VBD that_IN MIB-induced_NNP SKP_NNP 2_CD
          downregulation_NN at_IN the_DT protein_NN level_NN is_VBZ reflected_VBN by_IN
          quantitatively_RB similar_JJ changes_NNS in_IN steady_JJ state_NN RNA_NNP levels_NNS
          (_( Fig_NNP 3_CD A_DT )_) ._. In_IN contrast_NN ,_, p_NN 27_CD mRNA_NN levels_NNS were_VBD upregulated_JJ
          by_IN MIB_NNP only_RB two-fold_JJ (_( Fig_NNP ._. 3_LS A_DT )_) ._. This_DT suggested_VBD that_IN the_DT
          effect_NN of_IN MIB_NNP on_IN p_NN 27_CD RNA_NNP levels_NNS can_MD not_RB fully_RB account_VB for_IN
          the_DT accumulation_NN of_IN p_NN 27_CD protein_NN (_( compare_VB Figs_NNP ._. 2_LS Band_NNP
          3_CD A_DT )_)
          We_PRP therefore_RB determined_VBD the_DT effect_NN of_IN MIB_NNP on_IN p_NN 27_CD
          half-life_NN ._. Protein_NNP synthesis_NN was_VBD inhibited_VBD by_IN
          cycloheximide_NN in_IN control_NN cells_NNS and_CC in_IN cells_NNS pretreated_JJ
          with_IN MIB_NNP for_IN 72_CD h_NN ._. Cells_NNP were_VBD harvested_VBN after_IN various_JJ
          times_NNS and_CC the_DT effect_NN on_IN p_NN 27_CD protein_NN levels_NNS was_VBD assessed_VBN
          by_IN immunoblotting_VBG ._. Using_VBG this_DT assay_NN ,_, we_PRP determined_VBD a_DT p_NN 27_CD
          half-life_NN of_IN 4_CD h_NN in_IN control_NN cells_NNS ,_, which_WDT was_VBD increased_VBN to_TO
          more_JJR than_IN 6_CD h_NN in_IN MIB_NNP treated_VBD cells_NNS (_( Fig_NNP ._. 3_LS B_NNP )_) ._. This_DT
          experiment_NN likely_JJ overestimates_NNS p_NN 27_CD half-life_NN in_IN
          untreated_JJ cells_NNS ,_, as_IN SKP_NNP 2_CD was_VBD itself_PRP downregulated_JJ by_IN CHX_NNP
          (_( data_NNS not_RB shown_VBN )_) ._. Nevertheless_RB ,_, the_DT data_NNS suggest_VBP that_DT p_NN 27_CD
          upregulation_NN in_IN response_NN to_TO MIB_NNP is_VBZ partially_RB mediated_JJ by_IN
          changes_NNS in_IN protein_NN stability_NN ._.
          To_TO confirm_VB this_DT conjecture_NN ,_, we_PRP used_VBD an_DT 
          in_IN vitro_NN assay_NN to_TO determine_VB p_NN 27_CD
          ubiquitylation_NN activity_NN in_IN LNCaP_NNP cell_NN lysate_NN ._. Similar_JJ to_TO
          previously_RB described_VBD protocols_NNS [_NN 21_CD 22_CD 30_CD ]_NN ,_, cell_NN
          lysates_NNS were_VBD prepared_VBN by_IN hypotonic_JJ lysis_NNS of_IN untreated_JJ
          LNCaP_NNP cells_NNS or_CC cells_NNS treated_VBN with_IN MIB_NNP for_IN 96_CD h_NN ._.
          Ubiquitylation_NNP substrate_NN was_VBD prepared_VBN by_IN 
          in_IN vitro_NN transcription_NN and_CC
          translation_NN of_IN p_NN 27_CD in_IN the_DT presence_NN of_IN 35_CD S-_NNP methionine_NN ._. A_DT
          point_NN mutant_JJ of_IN p_NN 27_CD (_( p_NN 27_CD T_NN 187_CD A_DT )_) ,_, in_IN which_WDT the_DT critical_JJ
          CDK_NNP 2_CD phosphorylation_NN site_NN in_IN position_NN 187_CD was_VBD replaced_VBN by_IN
          alanine_NN [_NN 24_CD ]_NN was_VBD also_RB prepared_VBN ._. Both_DT substrates_NNS were_VBD
          incubated_JJ with_IN recombinant_JJ cyclin_NN E_NNP /_NN CDK_NNP 2_CD complexes_NNS in_IN the_DT
          presence_NN of_IN ATP_NNP ,_, ubiquitin_NN ,_, and_CC LNCaP_NNP cell_NN lysate_NN ._.
          Conversion_NNP of_IN p_NN 27_CD into_IN polyubiquitylated_JJ high_JJ molecular_JJ
          weight_NN species_NNS was_VBD monitored_VBN by_IN autoradiography_NN of_IN
          35_CD S-_NNP labeled_VBD p_NN 27_CD following_VBG gel_NN electrophoresis_NNS ._.
          Polyubiquitylation_NNP of_IN wildtype_NN ,_, but_CC not_RB mutant_JJ p_NN 27_CD was_VBD
          observed_VBN in_IN untreated_JJ LNCaP_NNP cell_NN lysate_NN (_( Fig_NNP ._. 3_LS C_NNP )_) ._. This_DT
          activity_NN was_VBD completely_RB abolished_VBN in_IN MIB-treated_NNP cells_NNS
          (_( Fig_NNP ._. 3_LS C_NNP )_) ,_, suggesting_VBG that_DT p_NN 27_CD accumulation_NN results_NNS from_IN
          reduced_VBN p_NN 27_CD ubiquitylation_NN ._.
        
        
          Overexpression_NNP of_IN SKP_NNP 2_CD induces_VBZ F-_NNP box-dependent_JJ p_NN 27_CD
          ubiquitylation_NN
          Considering_VBG the_DT inverse_NN correlation_NN between_IN p_NN 27_CD and_CC
          SKP_NNP 2_CD protein_NN levels_NNS ,_, we_PRP asked_VBD whether_IN ectopic_JJ SKP_NNP 2_CD can_MD
          forge_VB p_NN 27_CD down-regulation_JJ in_IN LNCaP_NNP cells_NNS ._. To_TO test_VB this_DT ,_,
          we_PRP generated_VBD recombinant_JJ adenoviruses_NNS driving_VBG the_DT
          expression_NN of_IN SKP_NNP 2_CD (_( Ad-_NNP SKP_NNP 2_LS )_) or_CC a_DT mutant_JJ of_IN SKP_NNP 2_CD lacking_VBG
          the_DT F-_NNP box_NN (_( Ad-_NNP SKP_NNP 2_CD -_: ΔF_NN )_) ._. Infection_NNP of_IN asynchronous_JJ LNCaP_NNP
          cells_NNS with_IN SKP_NNP 2_CD virus_NN led_VBN to_TO time-dependent_JJ
          downregulation_NN of_IN p_NN 27_CD (_( Fig_NNP ._. 4_LS A_DT )_) ._.
          To_TO determine_VB whether_IN SKP_NNP 2_CD downregulation_NN is_VBZ a_DT
          necessary_JJ step_NN in_IN MIB-induced_NNP p_NN 27_CD upregulation_NN ,_, LNCaP_NNP
          cells_NNS were_VBD blocked_VBN with_IN MIB_NNP for_IN 72_CD h_NN ,_, followed_VBN by_IN
          infection_NN with_IN Ad-_NNP SKP_NNP 2_CD or_CC Ad-_NNP SKP_NNP 2_CD -_: ΔF_NN for_IN various_JJ periods_NNS ._.
          Immunoblotting_NNP revealed_VBD that_IN SKP_NNP 2_CD overexpression_NN can_MD
          efficiently_RB downregulate_NN p_NN 27_CD levels_NNS in_IN the_DT continuous_JJ
          presence_NN of_IN MIB_NNP (_( Fig_NNP ._. 4_LS B_NNP )_) ._. In_IN contrast_NN ,_, overexpression_NN of_IN
          F-_NNP box_NN deleted_VBN SKP_NNP 2_CD did_VBD not_RB result_VB in_IN a_DT decline_NN of_IN p_NN 27_CD
          (_( Fig_NNP ._. 4_LS B_NNP )_) ._.
          To_TO determine_VB whether_IN SKP_NNP 2_CD induces_VBZ p_NN 27_CD ubiquitylation_NN ,_,
          cell_NN lysate_NN was_VBD prepared_VBN from_IN MIB-exposed_NNP cells_NNS infected_VBN
          with_IN Ad-_NNP SKP_NNP 2_CD and_CC Ad-_NNP SKP_NNP 2_CD -_: ΔF_NN ,_, and_CC supplemented_JJ with_IN
          phosphorylated_JJ p_NN 27_CD ,_, ATP_NNP ,_, and_CC ubiquitin_NN ._. SKP_NNP
          overexpression_NN for_IN 24_CD or_CC 48_CD h_NN dramatically_RB increased_VBD p_NN 27_CD
          ubiquitylation_NN activity_NN present_JJ in_IN these_DT cell_NN lysates_NNS
          (_( Fig_NNP ._. 4_LS C_NNP ,_, lane_NN 5_CD and_CC 7_CD )_) ._. This_DT increase_NN was_VBD not_RB observed_VBN
          with_IN mutant_JJ p_NN 27_CD T_NN 187_CD A_DT as_JJ substrate_NN and_CC upon_IN overexpression_NN
          of_IN SKP-ΔF_NNP (_( Fig_NNP ._. 4_LS C_NNP ,_, lanes_NNS 9_CD and_CC 11_CD )_) ._.
        
        
          Overexpression_NNP of_IN SKP_NNP 2_CD is_VBZ not_RB sufficient_JJ to_TO
          overcome_VB androgen-mediated_JJ G_NNP 1_CD arrest_NN
          To_TO test_VB whether_IN SKP_NNP 2_CD -_: mediated_JJ p_NN 27_CD degradation_NN is_VBZ
          sufficient_JJ to_TO overcome_VB the_DT MIB-induced_NNP G_NNP 1_CD cell_NN cycle_NN
          arrest_NN ,_, LNCaP_NNP cells_NNS were_VBD arrested_VBN with_IN MIB_NNP for_IN 72_CD h_NN ,_,
          followed_VBN by_IN infection_NN with_IN SKP_NNP 2_CD adenovirus_JJ ._. Cells_NNP were_VBD
          harvested_VBN and_CC analyzed_VBN by_IN flow_NN cytometry_NN after_IN various_JJ
          periods_NNS ._. The_DT mutant_JJ SKP_NNP 2_CD -_: ΔF_NN was_VBD used_VBN as_IN a_DT negative_JJ
          control_NN ._. Although_IN ,_, in_IN three_CD independent_JJ experiments_NNS ,_, the_DT
          fraction_NN of_IN cells_NNS in_IN S_NNP phase_NN was_VBD significantly_RB (_( p_NN =_SYM
          0_CD ._. 009_CD )_) higher_JJR in_IN MIB-arrested_NNP cells_NNS overexpressing_VBG SKP_NNP 2_CD
          (_( 7_CD ._. 93_CD %_NN ,_, +_NN /_NN -_: 0_CD ._. 32_CD )_) than_IN in_IN SKP_NNP 2_CD -_: ΔF_NN overexpressing_VBG cells_NNS
          (_( 4_CD ._. 02_CD %_NN ,_, +_NN /_NN -_: 1_CD ._. 41_CD )_) at_IN a_DT time_NN when_WRB p_NN 27_CD downregulation_NN was_VBD
          already_RB apparent_JJ (_( 24_CD h_NN )_) ,_, the_DT majority_NN of_IN cells_NNS remained_VBD
          tightly_RB arrested_VBN in_IN G_NNP 1_CD over_IN the_DT entire_JJ 72_CD h_NN course_NN of_IN the_DT
          experiment_NN (_( Fig_NNP ._. 5_LS A_DT )_) ._.
          This_DT finding_VBG is_VBZ in_IN contrast_NN to_TO serum_NN starved_VBN rat_NN
          fibroblasts_NNS and_CC human_JJ U_NNP 87_CD cells_NNS arrested_VBN in_IN G_NNP 1_CD by_IN
          overexpression_NN of_IN PTEN_NNP ,_, in_IN which_WDT SKP_NNP 2_CD overexpression_NN can_MD
          drive_VB S_NNP phase_NN entry_NN ._. [_NN 29_CD 30_CD 32_CD 33_CD ]_NN ._. In_IN both_DT cases_NNS ,_,
          SKP_NNP 2_CD overexpression_NN leads_VBZ to_TO induction_NN of_IN cyclin_NN A_DT and_CC
          CDK_NNP 2_CD kinase_NN activity_NN ._. We_PRP therefore_RB asked_VBD whether_IN
          SKP_NNP 2_CD -_: mediated_JJ p_NN 27_CD downregulation_NN in_IN MIB_NNP arrested_VBD LNCaP_NNP
          cells_NNS was_VBD able_JJ to_TO actually_RB bring_VB about_IN CDK_NNP 2_CD
          activation_NN ._.
          We_PRP first_RB determined_VBD the_DT effect_NN of_IN SKP_NNP 2_CD overexpression_NN
          on_IN MIB-induced_NNP RB_NNP 1_CD downregulation_NN and_CC accumulation_NN in_IN the_DT
          dephosphorylated_JJ state_NN (_( see_VB Fig_NNP ._. 2_LS A_DT )_) ,_, which_WDT is_VBZ carried_VBN
          out_IN by_IN CDK_NNP 2_CD 
          in_IN vivo_NN [_NN 47_CD ]_NN ._. Immunoblotting_NNP
          revealed_VBD that_IN RB_NNP 1_CD suppression_NN in_IN the_DT hypophosphorylated_JJ
          state_NN was_VBD efficiently_RB reversed_VBN by_IN SKP_NNP 2_CD overexpression_NN for_IN
          24_CD or_CC 48_CD h_NN (_( Fig_NNP ._. 5_LS B_NNP )_) ._. In_IN addition_NN ,_, cyclin_NN A_DT expression_NN
          was_VBD partially_RB restored_VBN (_( Fig_NNP ._. 5_LS B_NNP )_) ._. However_RB ,_, both_DT effects_NNS
          were_VBD largely_RB annihilated_JJ after_IN 72_CD h_NN of_IN SKP_NNP 2_CD
          overexpression_NN ._. In_IN contrast_NN ,_, cyclin_NN E_NNP levels_NNS ,_, while_IN not_RB
          initially_RB affected_VBN by_IN MIB_NNP ,_, were_VBD decreased_VBN after_IN 72_CD h_NN of_IN
          SKP_NNP 2_CD overexpression_NN (_( Fig_NNP ._. 5_LS B_NNP )_) ._. In_IN contrast_NN ,_, CDK_NNP 2_CD and_CC
          tubulin_NN levels_NNS remained_VBD stable_JJ at_IN all_DT time_NN points_NNS of_IN SKP_NNP 2_CD
          overexpression_NN (_( Fig_NNP ._. 5_LS B_NNP )_) ._.
          A_DT parallel_JJ experiment_NN ,_, revealed_VBD that_IN CDK_NNP 2_CD kinase_NN
          activity_NN assayed_JJ 
          in_IN vitro_NN using_VBG histone_NN 1_CD as_IN
          substrate_NN was_VBD suppressed_VBN by_IN MIB_NNP ,_, but_CC partially_RB restored_VBN
          by_IN overexpression_NN of_IN SKP_NNP 2_CD for_IN 24_CD and_CC 48_CD h_NN (_( Fig_NNP ._. 5_LS C_NNP ,_, left_VBD
          panel_NN )_) ._. This_DT increase_NN was_VBD paralleled_JJ by_IN a_DT decrease_NN in_IN the_DT
          amount_NN of_IN p_NN 27_CD associated_VBN with_IN cyclin_NN E_NNP (_( Fig_NNP ._. 5_LS C_NNP ,_, right_JJ
          panel_NN )_) ._. While_IN this_DT decrease_NN was_VBD maintained_VBN throughout_IN the_DT
          course_NN of_IN the_DT experiment_NN ,_, CDK_NNP 2_CD activation_NN was_VBD attenuated_JJ
          again_RB at_IN 72_CD h_NN of_IN SKP_NNP 2_CD overexpression_NN ._. In_IN summary_NN ,_, SKP_NNP 2_CD
          overexpression_NN caused_VBD transient_JJ upregulation_NN of_IN cyclin_NN A_DT
          expression_NN and_CC CDK_NNP 2_CD activity_NN ,_, but_CC was_VBD inefficient_JJ in_IN
          promoting_VBG S_NNP phase_NN entry_NN of_IN MIB-arrested_NNP LNCaP_NNP cells_NNS ._.
        
      
      
        Discussion_NNP
        
          Androgen_NNP control_NN of_IN LNCaP_NNP cell_NN proliferation_NN
          We_PRP have_VBP used_VBN the_DT cell_NN line_NN LNCaP_NNP as_IN a_DT model_NN to_TO examine_VB
          the_DT role_NN of_IN SKP_NNP 2_CD in_IN androgen_NN control_NN of_IN p_NN 27_CD expression_NN
          and_CC cell_NN cycle_NN progression_NN in_IN human_JJ prostate_NN cancer_NN
          cells_NNS ._. LNCaP_NNP cells_NNS exhibit_NN a_DT complex_NN ,_, but_CC characteristic_JJ
          biphasic_JJ response_NN to_TO androgens_NNS :_: (_( 1_CD ._. )_) Stimulation_NNP of_IN
          proliferation_NN at_IN low_JJ androgen_NN levels_NNS ,_, and_CC (_( 2_CD ._. )_) inhibition_NN
          of_IN proliferation_NN at_IN higher_JJR levels_NNS such_JJ as_IN those_DT used_VBN in_IN
          this_DT study_NN [_NN 41_CD ]_NN ._. This_DT dichotomy_NN was_VBD compared_VBN [_NN 43_CD ]_NN to_TO
          the_DT situation_NN in_IN male_JJ rodents_NNS ,_, where_WRB castration_NN leads_VBZ to_TO
          atrophy_NN of_IN the_DT prostate_NN due_JJ to_TO apoptosis_NNS ._.
          Re-administration_NNP of_IN androgen_NN induces_VBZ transient_JJ
          epithelial_NN cell_NN proliferation_NN ,_, presumably_RB mediated_JJ by_IN
          proteolytic_JJ downregulation_NN of_IN p_NN 27_CD ,_, until_IN pre-castration_JJ
          cell_NN numbers_NNS have_VBP been_VBN restored_VBN [_NN 48_CD 49_CD ]_NN ._. No_DT further_JJ
          proliferation_NN ensues_NNS beyond_IN this_DT point_NN ,_, at_IN which_WDT p_NN 27_CD
          levels_NNS are_VBP increased_VBN again_RB ,_, despite_IN the_DT continuous_JJ
          presence_NN of_IN androgen_NN ._. This_DT may_MD reflect_VB androgen_NN activity_NN
          in_IN restoring_VBG the_DT glandular_NN structure_NN by_IN promoting_VBG
          postmitotic_JJ differentiation_NN [_NN 48_CD 49_CD ]_NN ._. Consistent_NNP with_IN
          this_DT view_NN ,_, androgen_NN administration_NN to_TO intact_JJ rats_NNS
          resulted_VBD in_IN suppression_NN of_IN prostate_NN epithelial_NN cell_NN
          proliferation_NN and_CC maintenance_NN of_IN morphological_JJ gland_NN
          integrity_NN [_NN 50_CD ]_NN ._. Based_VBN on_IN these_DT findings_NNS ,_, we_PRP propose_VBP
          that_IN the_DT effects_NNS of_IN high_JJ doses_NNS of_IN androgens_NNS on_IN SKP_NNP 2_CD and_CC
          p_NN 27_CD in_IN LNCaP_NNP cells_NNS described_VBD here_RB reflect_VB a_DT
          differentiation_NN and_CC consolidation_NN effect_NN 
          in_IN vitro_NN ._. If_IN this_DT is_VBZ the_DT case_NN ,_,
          LNCaP_NNP cells_NNS ,_, despite_IN being_VBG highly_RB aneuploid_NN derivatives_NNS
          of_IN a_DT metastatic_JJ lesion_NN of_IN an_DT advanced_VBN cancer_NN [_NN 39_CD ]_NN ,_, may_MD
          have_VB retained_VBN some_DT aspects_NNS of_IN the_DT normal_JJ biphasic_JJ
          mechanism_NN of_IN androgen_NN control_NN observed_VBD in_IN castrated_JJ
          rodents_NNS ._. This_DT mechanism_NN may_MD also_RB be_VB retained_VBN in_IN other_JJ
          prostate_NN cancers_NNS ,_, thereby_RB representing_VBG a_DT potential_JJ target_NN
          for_IN intervention_NN ._.
        
        
          Role_NNP of_IN SKP_NNP 2_CD in_IN androgen_NN control_NN of_IN p_NN 27_CD
          stability_NN
          Our_PRP$ data_NNS indicate_VBP that_IN SKP_NNP 2_CD is_VBZ an_DT integral_JJ component_NN
          of_IN androgen_NN control_NN in_IN LNCaP_NNP cells_NNS ,_, as_IN it_PRP is_VBZ
          down-regulated_JJ in_IN an_DT AR-mediated_NNP manner_NN (_( Fig_NNP ._. 2_LS Band_NNP 2_CD C_NNP )_) ._.
          In_IN contrast_NN ,_, all_DT other_JJ known_VBN SCF_NNP SKP_NNP 2_CD subunits_NNS examined_VBD
          were_VBD largely_RB unresponsive_JJ to_TO androgen_NN (_( Fig_NNP ._. 2_LS A_DT )_) ._.
          Importantly_NNP ,_, SKP_NNP 2_CD overexpression_NN is_VBZ sufficient_JJ to_TO reverse_VB
          androgen-mediated_JJ p_NN 27_CD accumulation_NN and_CC induce_VB p_NN 27_CD
          ubiquitylation_NN (_( Fig_NNP ._. 4_LS Band_NNP 4_CD D_NNP )_) ._. Based_VBN on_IN the_DT F-_NNP box_NN
          dependency_NN of_IN these_DT processes_VBZ (_( Fig_NNP ._. 4_LS C_NNP )_) ,_, we_PRP conclude_VBP that_IN
          SKP_NNP 2_CD directly_RB triggers_VBZ the_DT ubiquitylation_NN and_CC degradation_NN
          of_IN p_NN 27_CD in_IN LNCaP_NNP cells_NNS ,_, a_DT process_NN which_WDT is_VBZ attenuated_JJ by_IN
          androgen-mediated_JJ SKP_NNP 2_CD downregulation_NN ._. This_DT
          interpretation_NN is_VBZ consistent_JJ with_IN SKP_NNP 2_CD being_VBG a_DT proximal_NN
          element_NN in_IN the_DT previously_RB identified_VBN androgen-mediated_JJ
          pathway_NN of_IN cell_NN cycle_NN inhibition_NN in_IN LNCaP_NNP cells_NNS ._. As_IN a_DT
          direct_JJ consequence_NN of_IN SKP_NNP 2_CD downregulation_NN ,_, p_NN 27_CD is_VBZ
          upregulated_JJ and_CC cyclin_NN A_DT is_VBZ downregulated_JJ ._. This_DT results_NNS
          in_IN inhibition_NN of_IN CDK_NNP 2_CD activity_NN ,_, accumulation_NN of_IN
          hypophosphorylated_JJ RB_NNP 1_CD ,_, inactivation_NN of_IN E_NNP 2_CD F_NN 1_CD [_NN 45_CD ]_NN ,_, and_CC
          cell_NN cycle_NN arrest_NN ._.
          While_IN it_PRP may_MD surprise_VB that_IN SKP_NNP 2_CD overexpression_NN alone_RB
          is_VBZ sufficient_JJ to_TO mediate_VB p_NN 27_CD degradation_NN in_IN LNCaP_NNP cells_NNS ,_,
          given_VBN the_DT known_VBN requirement_NN for_IN p_NN 27_CD phosphorylation_NN [_NN 24_CD
          ]_NN ,_, similar_JJ observations_NNS were_VBD made_VBN in_IN rat_NN fibroblasts_NNS ,_,
          human_JJ U_NNP 87_CD cells_NNS ,_, and_CC primary_JJ rat_NN hepatocytes_NNS [_NN 29_CD 30_CD 31_CD
          32_CD ]_NN ._. In_IN rat_NN fibroblasts_NNS ,_, these_DT findings_NNS correlate_VBP with_IN
          SKP_NNP 2_CD -_: induced_VBN upregulation_NN of_IN cyclin_NN A_DT and_CC CDK_NNP 2_CD kinase_NN
          activity_NN [_NN 29_CD 32_CD ]_NN ,_, which_WDT could_MD further_RB augment_VB p_NN 27_CD
          phosphorylation_NN and_CC degradation_NN ,_, ultimately_RB stimulating_VBG
          cells_NNS to_TO enter_VB S_NNP phase_NN ._.
          Unlike_IN in_IN rat_NN fibroblasts_NNS and_CC human_JJ U_NNP 87_CD cells_NNS [_NN 29_CD 30_CD
          32_CD ]_NN ,_, SKP_NNP 2_CD overexpression_NN is_VBZ not_RB sufficient_JJ to_TO override_VB
          androgen-induced_JJ G_NNP 1_CD arrest_NN in_IN LNCaP_NNP cells_NNS ,_, despite_IN a_DT
          profound_JJ effect_NN on_IN p_NN 27_CD levels_NNS (_( Fig_NNP ._. 5_LS )_) ._. Consistent_NNP with_IN
          this_DT finding_NN ,_, ectopic_JJ SKP_NNP 2_CD expression_NN was_VBD not_RB sufficient_JJ
          to_TO maintain_VB high_JJ cyclin_NN A_DT levels_NNS ,_, CDK_NNP 2_CD activation_NN ,_, and_CC
          RB_NNP 1_CD phosphorylation_NN for_IN prolonged_JJ periods_NNS (_( Fig_NNP ._. 5_LS Band_NNP
          5_CD C_NNP )_) ._. The_DT transient_JJ character_NN of_IN these_DT responses_NNS may_MD
          explain_VB the_DT failure_NN to_TO cause_VB efficient_JJ S_NNP phase_NN entry_NN in_IN
          the_DT presence_NN of_IN MIB_NNP ,_, in_IN particular_JJ as_IN co-expression_JJ of_IN
          cyclins_NNS was_VBD previously_RB shown_VBN to_TO synergize_NN with_IN SKP_NNP 2_CD in_IN
          stimulating_VBG CDK_NNP 2_CD activity_NN and_CC S_NNP phase_NN entry_NN [_NN 30_CD 31_CD ]_NN ._.
          In_IN addition_NN ,_, cyclin_NN A_DT is_VBZ frequently_RB overexpressed_JJ in_IN
          prostate_NN cancers_NNS [_NN 51_CD ]_NN ._. In_IN future_JJ experiments_NNS ,_, it_PRP will_MD
          be_VB interesting_JJ to_TO determine_VB the_DT effect_NN of_IN combined_VBN
          overexpression_NN of_IN SKP_NNP 2_CD and_CC cyclin_NN A_DT and_CC cyclin_NN E_NNP on_IN cell_NN
          cycle_NN progression_NN of_IN MIB-arrested_NNP cells_NNS ._.
          Regardless_RB of_IN the_DT outcome_NN of_IN such_JJ experiments_NNS ,_, our_PRP$
          data_NNS firmly_RB suggest_VBP that_IN SKP_NNP 2_CD is_VBZ a_DT central_JJ mediator_NN of_IN
          the_DT androgen_NN response_NN mechanism_NN of_IN LNCaP_NNP cells_NNS ._. However_RB ,_,
          we_PRP do_VBP not_RB believe_VB that_IN SKP_NNP 2_CD is_VBZ a_DT direct_JJ transcriptional_NN
          target_NN of_IN the_DT AR_NNP ,_, as_IN the_DT kinetics_NNS of_IN its_PRP$ downregulation_NN
          were_VBD rather_RB slow_JJ (_( Fig_NNP ._. 2_LS A_DT )_) ,_, suggesting_VBG several_JJ
          intermediate_JJ steps_NNS culminating_VBG in_IN this_DT event_NN ._. Such_JJ a_DT
          mediator_NN could_MD be_VB AS_NNP 3_CD ,_, a_DT gene_NN induced_VBN by_IN growth_NN
          inhibiting_VBG levels_NNS of_IN androgen_NN with_IN kinetics_NNS that_WDT precede_VB
          cell_NN cycle_NN arrest_NN [_NN 52_CD ]_NN ._. In_IN addition_NN ,_, AS_NNP 3_CD
          overexpression_NN mimics_VBZ androgen-mediated_JJ cell_NN cycle_NN arrest_NN
          in_IN MCF_NNP 7_CD cells_NNS stably_RB expressing_VBG exogenous_JJ AR_NNP ,_, while_IN
          anti-sense_JJ AS_NNP 3_CD confers_VBZ resistance_NN to_TO androgen-induced_JJ
          growth_NN arrest_NN [_NN 53_CD ]_NN ._. The_DT function_NN of_IN AS_NNP 3_CD is_VBZ still_RB
          unknown_JJ ,_, but_CC the_DT encoded_JJ protein_NN has_VBZ features_NNS of_IN a_DT
          potential_JJ transcription_NN factor_NN [_NN 53_CD ]_NN ._.
          While_IN our_PRP$ study_NN suggests_VBZ that_IN SKP_NNP 2_CD is_VBZ an_DT important_JJ
          player_NN in_IN p_NN 27_CD regulation_NN in_IN prostate_NN cancer_NN cells_NNS ,_, recent_JJ
          studies_NNS have_VBP also_RB implicated_VBN another_DT protein_NN ,_, CSN_NNP 5_CD /_NN JAB_NNP 1_CD ,_,
          in_IN p_NN 27_CD regulation_NN [_NN 54_CD 55_CD ]_NN ._. CSN_NNP 5_CD is_VBZ a_DT subunit_NN of_IN the_DT
          COP_NNP 9_CD /_NN signalosome_NN (_( CSN_NNP )_) complex_JJ [_NN 56_CD 57_CD 58_CD 59_CD ]_NN ,_, but_CC also_RB
          forms_VBZ distinct_JJ complexes_NNS apparently_RB lacking_VBG CSN_NNP subunits_NNS
          [_NN 55_CD 60_CD 61_CD 62_CD ]_NN ._. Overexpression_NNP of_IN CSN_NNP 5_CD in_IN NIH_NNP 3_CD T_NN 3_CD cells_NNS
          causes_NNS p_NN 27_CD export_NN from_IN the_DT nucleus_NN and_CC ectopic_JJ
          degradation_NN [_NN 54_CD ]_NN ._. Notably_RB ,_, like_IN SKP_NNP 2_CD [_NN 33_CD 36_CD 37_CD 38_CD ]_NN ,_,
          CSN_NNP 5_CD was_VBD found_VBN to_TO be_VB overexpressed_JJ in_IN cancers_NNS devoid_JJ of_IN
          p_NN 27_CD [_NN 63_CD ]_NN ._. However_RB ,_, our_PRP$ studies_NNS did_VBD not_RB reveal_VB any_DT
          effect_NN of_IN MIB_NNP on_IN CSN_NNP 5_CD expression_NN ._. Future_JJ studies_NNS aimed_VBN at_IN
          eliminating_VBG CSN_NNP 5_CD activity_NN will_MD show_VB whether_IN it_PRP is_VBZ
          involved_VBN in_IN androgen-mediated_JJ p_NN 27_CD control_NN ._.
          Finally_RB ,_, a_DT recent_JJ report_NN demonstrated_VBD SKP_NNP 2_CD -_: independent_JJ
          proteolysis_NNS of_IN p_NN 27_CD in_IN lymphocytes_NNS derived_VBN from_IN SKP_NNP 2_CD
          knockout_NN mice_NNS [_NN 64_CD ]_NN ._. It_PRP is_VBZ thus_RB possible_JJ that_DT p_NN 27_CD
          proteolysis_NNS is_VBZ subject_JJ to_TO tissue-specific_JJ regulation_NN ._. In_IN
          prostate_NN cells_NNS ,_, however_RB ,_, SKP_NNP 2_CD seems_VBZ to_TO be_VB a_DT major_JJ
          determinant_NN of_IN p_NN 27_CD degradation_NN ,_, as_IN it_PRP is_VBZ down-regulated_JJ
          by_IN androgen_NN and_CC its_PRP$ overexpression_NN is_VBZ sufficient_JJ to_TO
          mediate_VB p_NN 27_CD ubiquitylation_NN and_CC degradation_NN ._. Recent_JJ
          studies_NNS involving_VBG androgen_NN administration_NN to_TO castrated_JJ
          rats_NNS have_VBP come_VBN to_TO similar_JJ conclusions_NNS [_NN 49_CD ]_NN ._.
        
      
      
        Conclusions_NNP
        Our_PRP$ data_NNS suggest_VBP that_IN androgen-mediated_JJ SKP_NNP 2_CD
        downregulation_NN is_VBZ responsible_JJ for_IN decreased_VBD ubiquitylation_NN
        and_CC accumulation_NN of_IN p_NN 27_CD in_IN LNCaP_NNP cells_NNS ,_, an_DT effect_NN that_WDT is_VBZ
        readily_RB overcome_VBN by_IN overexpression_NN of_IN SKP_NNP 2_CD ._. We_PRP propose_VBP that_IN
        frequent_JJ p_NN 27_CD downregulation_NN in_IN prostate_NN cancer_NN may_MD be_VB
        caused_VBN by_IN SKP_NNP 2_CD overexpression_NN thus_RB enabling_VBG escape_NN from_IN
        normal_JJ androgen_NN control_NN ._. Finally_RB ,_, our_PRP$ 
        in_IN vitro_NN studies_NNS validate_NN the_DT SKP_NNP 2_CD
        pathway_NN as_IN a_DT potential_JJ target_NN for_IN therapeutic_JJ intervention_NN
        in_IN cancers_NNS devoid_JJ of_IN p_NN 27_CD ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Plasmids_NNP and_CC reagents_NNS
          Human_NNP SKP_NNP 2_CD and_CC p_NN 27_CD cDNAs_NNS were_VBD kindly_RB provided_VBN by_IN H_NNP ._.
          Zhang_NNP (_( Yale_NNP University_NNP )_) and_CC P_NN ._. Jackson_NNP (_( Stanford_NNP
          University_NNP )_) ._. The_DT genes_NNS were_VBD amplified_VBN by_IN PCR_NNP and_CC cloned_VBN
          into_IN pcDNA_NN 3_CD enabling_VBG 
          in_IN vitro_NN transcription_NN ._. The_DT SKP_NNP 2_CD
          mutant_JJ lacking_VBG the_DT F-_NNP box_NN was_VBD constructed_VBN using_VBG the_DT
          Quickchange_NNP kit_NN purchased_VBN from_IN Stratagene_NNP ._. Probes_NNP for_IN
          Northern_NNP blotting_VBG were_VBD generated_VBN by_IN PCR_NNP ._. The_DT GAPDH_NNP probe_NN
          was_VBD generated_VBN by_IN reverse_NN transcription_NN and_CC PCR_NNP from_IN LNCaP_NNP
          m_NN RNA_NNP ._.
          The_DT synthetic_JJ androgen_NN mibolerone_NN
          (_( 7_CD α-_NN 17_CD α-dimethyl-_JJ 19_CD -_: nortestosterone_NN )_) was_VBD purchased_VBN from_IN
          Perkin_NNP Elmer_NNP Life_NNP Sciences_NNPS ._. The_DT antiandrogen_NN cyproterone_NN
          acetate_NN was_VBD a_DT gift_NN from_IN C_NNP ._. Sonnenschein_NNP (_( Tufts_NNP
          University_NNP )_) ._. The_DT reagents_NNS were_VBD dissolved_VBN in_IN absolute_JJ
          ethanol_NN ._.
          Antibodies_NNP :_: SKP_NNP 2_CD (_( Zymed_NNP 32_CD -_: 3300_CD ,_, 1_CD :_: 250_CD for_IN
          immunoblotting_VBG )_) ,_, SKP_NNP 2_CD (_( Santa_NNP Cruz_NNP sc-_NN 7164_CD ,_, 1_CD :_: 500_CD for_IN
          immunofluorescence_NN staining_VBG )_) ,_, p_NN 27_CD (_( Transduction_NNP
          Laboratories_NNPS K_NNP 25030_CD ,_, 1_CD :_: 5000_CD for_IN immunoblotting_VBG ,_, 1_CD :_: 1000_CD
          for_IN immunofluorescence_NN staining_VBG )_) ,_, cyclin_NN A_DT (_( Neomarkers_NNP
          Ab-_NNP 6_CD ,_, MS-_NNP 1061_CD ,_, 1_CD :_: 100_CD for_IN immunoblotting_VBG )_) ,_, cyclin_NN E_NNP
          (_( Neomarkers_NNP Ab-_NNP 1_CD ,_, RB-_NNP 012_CD ,_, 2_CD ug_NN per_IN immunoprecipitation_NN )_)
          cyclin_NN E_NNP (_( Neomarkers_NNP Ab-_NNP 2_CD ,_, MS-_NNP 870_CD ,_, 1_CD :_: 200_CD for_IN
          immunoblotting_VBG )_) ,_, HRT_NNP 1_CD (_( affinity-purified_JJ rabbit_NN
          polyclonal_NN ,_, gift_NN from_IN R_NN ._. Deshaies_NNP ,_, 1_CD :_: 1000_CD for_IN
          immunoblotting_VBG )_) ,_, CUL_NNP 1_CD (_( Zymed_NNP 71_CD -_: 8700_CD ,_, 1_CD :_: 250_CD for_IN
          immunoblotting_VBG )_) ,_, SKP_NNP 1_CD (_( Transduction_NNP laboratories_NNS 610530_CD ,_,
          1_CD :_: 5000_CD for_IN immunoblotting_VBG )_) ,_, JAB_NNP 1_CD /_NN CSN_NNP 5_CD (_( GeneTex_NNP
          MS-Jab_NNP 11_CD -_: PX_NNP 1_CD ,_, 1_CD :_: 1000_CD for_IN immunoblotting_VBG )_) ,_, RB_NNP 1_CD (_( Pharmingen_NNP
          554136_CD ,_, 1_CD :_: 500_CD for_IN immunoblotting_VBG )_) ,_, CDK_NNP 2_CD (_( Santo_NNP Cruz_NNP
          Biotechnology_NNP sc-_NN 163_CD ,_, 2_CD ug_NN per_IN immunoprecipitation_NN ,_, 1_CD :_: 500_CD
          for_IN immunoblotting_VBG )_) ,_, Tubulin_NNP (_( Sigma_NNP T_NN 5168_CD ,_, 1_CD :_: 2000_CD for_IN
          immunoblotting_VBG )_) ._.
        
        
          Tissue_NNP culture_NN
          LNCaP-FGC_NNP cells_NNS were_VBD obtained_VBN from_IN ATCC_NNP (_( order_NN number_NN
          CRL-_NNP 10995_CD )_) and_CC maintained_VBN in_IN RPMI_NNP supplemented_JJ with_IN 10_CD %_NN
          FBS_NNP as_IN described_VBN [_NN 46_CD ]_NN ._. We_PRP noticed_VBD that_IN LNCaP_NNP cells_NNS at_IN
          low_JJ density_NN grow_VB best_JJS on_IN 15_CD cm_NN Falcon_NNP 3025_CD tissue_NN culture_NN
          dishes_NNS and_CC that_IN the_DT effects_NNS of_IN SKP_NNP 2_CD overexpression_NN were_VBD
          most_RBS pronounced_VBN when_WRB cells_NNS were_VBD cultured_JJ on_IN these_DT dishes_NNS
          (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Adenoviruses_NNP
          For_IN production_NN of_IN adenoviruses_NNS ,_, the_DT ADEASY_NNP system_NN was_VBD
          used_VBN (_( generously_RB provided_VBN by_IN B_NNP ._. Vogelstein_NNP )_) ._. The_DT complete_JJ
          SKP_NNP 2_CD cDNA_NN or_CC a_DT mutant_JJ lacking_VBG the_DT F-_NNP box_NN (_( SKP_NNP 2_CD -_: ΔF_NN )_) were_VBD
          cloned_VBN into_IN a_DT modified_VBN pcDNA_NN 3_CD plasmid_NN providing_VBG an_DT
          N-_NNP terminal_NN Myc_NNP epitope_NN tag_NN and_CC the_DT human_JJ lamin_NN B_NNP leader_NN
          sequence_NN ._. The_DT lamin_NN B-SKP_NNP 2_CD cassette_NN was_VBD removed_VBN and_CC
          cloned_VBN into_IN the_DT pADTRACK_NN 1_CD shuttle_NN vector_NN ._. The_DT resulting_VBG
          plasmid_NN was_VBD transformed_VBN into_IN BJ-ADEASY_NNP cells_NNS by_IN
          electroporation_NN ._. Adenoviral_NNP DNA_NNP generated_VBN by_IN
          recombination_NN in_IN BJ-ADEASY_NNP cells_NNS was_VBD isolated_VBN ._.
          Recombinant_NNP adenoviral_NN DNA_NNP was_VBD transfected_JJ into_IN 293_CD cells_NNS
          using_VBG standard_JJ calcium_NN phosphate_NN procedures_NNS ._. Virus_NNP was_VBD
          harvested_VBN from_IN cells_NNS and_CC amplified_VBN by_IN infection_NN of_IN 293_CD
          cells_NNS ._. Amplified_NNP virus_NN was_VBD purified_JJ by_IN cesium_NN chloride_NN
          gradient_NN centrifugation_NN and_CC tittered_JJ ._. An_DT approximate_JJ
          multiplicity_NN of_IN infection_NN of_IN 100_CD was_VBD used_VBN throughout_IN ._.
        
        
          Immunological_NNP techniques_NNS
          Cell_NNP lysates_NNS for_IN immunoblotting_VBG were_VBD prepared_VBN by_IN
          scraping_VBG cells_NNS into_IN heated_JJ 2_CD ×_NN SDS_NNP sample_NN buffer_NN ._. Samples_NNP
          were_VBD boiled_VBD for_IN 10_CD min_NN ,_, centrifuged_JJ ,_, and_CC separated_VBN by_IN SDS_NNP
          gel_NN electrophoresis_NNS ._. Proteins_NNPS were_VBD transferred_VBN onto_IN
          Immobilon_NNP P_NN membrane_NN (_( Millipore_NNP )_) ,_, blocked_VBN in_IN 5_CD %_NN nonfat_JJ
          dry_JJ milk_NN dissolved_VBN in_IN tris-buffered_JJ saline_NN /_NN 0_CD ._. 1_CD %_NN Tween_NNP
          and_CC probed_JJ with_IN the_DT various_JJ antibodies_NNS ._.
          Cell_NNP lysates_NNS for_IN immunoprecipitation_NN were_VBD prepared_VBN in_IN
          IP-LB_NNP (_( 25_CD mM_NN Tris_NNP ,_, pH_NN 7_CD ._. 4_CD ,_, 150_CD mM_NN NaCl_NNP ,_, 0_CD ._. 5_CD %_NN Triton_NNP
          X_NNP 100_CD ,_, 10_CD μg_NN /_NN ml_NN leupeptin_NN ,_, 10_CD μg_NN /_NN ml_NN pepstatin_NN ,_, 1_CD mM_NN PMSF_NNP ,_,
          17_CD μg_NN /_NN ml_NN aprotinin_NN )_) ._. Cells_NNP were_VBD scraped_JJ into_IN IP-LB_NNP and_CC
          incubated_JJ on_IN ice_NN for_IN 30_CD min_NN ._. Cell_NNP lysate_NN was_VBD cleared_VBN by_IN
          centrifugation_NN and_CC the_DT supernatant_NN was_VBD incubated_JJ with_IN
          various_JJ antibodies_NNS (_( see_VB plasmid_NN and_CC reagents_NNS section_NN
          above_IN )_) ._. Immunocomplexes_NNP were_VBD collected_VBN on_IN protein_NN A_DT or_CC G_NNP
          beads_NNS ,_, washed_VBD five_CD times_NNS in_IN IP-LB_NNP for_IN 5_CD minutes_NNS each_DT ,_,
          dissolved_VBN in_IN 2_CD ×_NN SDS_NNP sample_NN buffer_NN ,_, and_CC separated_VBN by_IN SDS_NNP
          gel_NN electrophoresis_NNS ._.
          For_IN immunofluorescence_NN staining_VBG ,_, LNCaP_NNP cells_NNS were_VBD
          plated_JJ onto_IN poly-lysine_JJ coated_JJ glass_NN coverslips_NNS ._. Cells_NNP
          were_VBD fixed_VBN in_IN 4_CD %_NN para-formaldehyde_JJ in_IN PBS_NNP and_CC
          permeabilized_JJ by_IN washing_VBG in_IN PBS_NNP /_NN 0_CD ._. 1_CD %_NN Triton_NNP X_NNP 100_CD ._.
          Coverslips_NNP were_VBD blocked_VBN in_IN PBS_NNP /_NN 0_CD ._. 1_CD %_NN Triton_NNP X_NNP 100_CD
          containing_VBG 5_CD %_NN nonfat_JJ dry_JJ milk_NN for_IN 45_CD min_NN ._. Incubation_NNP
          with_IN primary_JJ and_CC secondary_JJ antibodies_NNS was_VBD in_IN the_DT same_JJ
          buffer_NN for_IN 45_CD min_NN each_DT ._. After_IN antibody_NN incubations_NNS ,_,
          coverslips_NNS were_VBD washed_VBN five_CD times_NNS in_IN PBS_NNP /_NN 0_CD ._. 1_CD %_NN Triton_NNP
          X_NNP 100_CD ,_, followed_VBN by_IN mounting_VBG on_IN microscopy_NN slides_NNS ._.
          Micrographs_NNP were_VBD taken_VBN with_IN a_DT Spot_NNP CCD_NNP camera_NN mounted_VBD on_IN
          a_DT Nikon_NNP E_NNP 600_CD epifluorescence_NN microscope_NN ._. Brightness_NNP and_CC
          contrast_NN of_IN the_DT images_NNS was_VBD adjusted_VBN in_IN Adobe_NNP Photoshop_NNP
          5_CD ._. 0_CD ._.
        
        
          Northern_NNP blotting_VBG
          Isolation_NNP of_IN total_JJ cellular_JJ RNA_NNP using_VBG a_DT urea_NN /_NN LiCl_NNP
          protocol_NN and_CC gel_NN electrophoresis_NNS was_VBD performed_VBN as_IN
          described_VBN previously_RB [_NN 65_CD ]_NN ._. Gels_NNP were_VBD transferred_VBN onto_IN
          Amersham_NNP Hybond_NNP N_NNP +_NN nylon_NN membranes_NNS in_IN 20_CD ×_NN SSC_NNP and_CC
          prehybridized_JJ in_IN 4_CD ×_NN SSC_NNP ,_, 1_CD ×_NN Denhardt_NNP 's_POS solution_NN ,_, 0_CD ._. 5_CD %_NN
          SDS_NNP for_IN 2_CD h_NN at_IN 68_CD °_NN C_NNP ._. Complementary_NNP DNA_NNP fragments_NNS for_IN
          SKP_NNP 2_CD ,_, p_NN 27_CD ,_, and_CC GAPDH_NNP were_VBD amplified_VBN by_IN PCR_NNP and_CC
          radiolabeled_JJ by_IN random_JJ priming_VBG ._. Filters_NNP were_VBD hybridized_JJ
          for_IN 16_CD h_NN at_IN 68_CD °_NN C_NNP followed_VBN by_IN washing_VBG in_IN 2_CD ×_NN SSC_NNP at_IN 68_CD °_NN C_NNP ._.
          Membranes_NNP were_VBD exposed_VBN to_TO X-_NNP ray_NN film_NN for_IN 2_CD to_TO 12_CD h_NN and_CC
          scanned_JJ with_IN a_DT phosphoimager_NN for_IN signal_NN quantitation_NN ._.
        
        
          H_NNP 1_CD kinase_NN assay_NN
          Histone_NNP 1_CD kinase_NN assays_NNS with_IN cyclin_NN E_NNP or_CC CDK_NNP 2_CD
          immunoprecipitates_NNS were_VBD performed_VBN as_IN described_VBN [_NN 65_CD ]_NN
          ._.
        
        
          In_IN vitroubiquitylation_NN assay_NN
          Cell_NNP lysates_NNS for_IN ubiquitylation_NN assays_NNS were_VBD prepared_VBN
          by_IN hypotonic_JJ lysis_NNS on_IN ice_NN in_IN 20_CD mM_NN Hepes_NNP pH_NN 7_CD ._. 5_CD ,_, 15_CD mM_NN
          MgCl_NNP 
          2_CD ,_, 5_CD mM_NN KCl_NNP ,_, 1_CD mM_NN DTT_NNP ,_, 10_CD μg_NN /_NN ml_NN
          leupeptin_NN ,_, 10_CD μg_NN /_NN ml_NN pepstatin_NN ,_, 1_CD mM_NN PMSF_NNP ,_, 17_CD μg_NN /_NN ml_NN
          aprotinin_NN as_IN described_VBN previously_RB [_NN 30_CD ]_NN ._. Lysates_NNP were_VBD
          cleared_VBN by_IN centrifugation_NN and_CC used_VBN without_IN prior_JJ
          freezing_NN ._. Radiolabeled_NNP wildtype_NN and_CC T_NN 178_CD A_DT point_NN mutant_JJ
          p_NN 27_CD were_VBD produced_VBN by_IN combined_VBN 
          in_IN vitro_NN transcription_NN and_CC
          translation_NN in_IN rabbit_NN reticulocyte_NN lysate_NN containing_VBG
          35_CD S-_NNP methionine_NN ._. The_DT 
          in_IN vitro_NN translated_VBN proteins_NNS were_VBD
          incubated_JJ 2_CD h_NN at_IN 30_CD °_NN C_NNP in_IN the_DT presence_NN of_IN 1_CD mM_NN ATP_NNP with_IN
          recombinant_JJ cyclin_NN E_NNP /_NN CDK_NNP 2_CD complexes_NNS produced_VBN from_IN
          baculoviruses_NNS in_IN insect_NN cells_NNS ._. Aliquots_NNP of_IN phosphorylated_JJ
          proteins_NNS were_VBD added_VBN to_TO a_DT reaction_NN containing_VBG 120_CD μg_NN cell_NN
          lysate_NN ,_, recombinant_JJ human_JJ E_NNP 1_CD ,_, 0_CD ._. 25_CD mg_NN /_NN ml_NN ubiquitin_NN ,_, 1_CD μM_NN
          ubiquitin_NN aldehyde_NN ,_, 1_CD μM_NN okadaic_JJ acid_NN ,_, 20_CD μM_NN MG_NNP 132_CD ,_, and_CC
          ATP_NNP regenerating_VBG system_NN (_( 20_CD mM_NN ATP_NNP ,_, 10_CD mM_NN creatine_NN
          phosphate_NN ,_, 0_CD ._. 1_CD μg_NN /_NN ml_NN creatine_NN kinase_NN )_) ._. After_IN 90_CD min_NN ,_, the_DT
          reactions_NNS were_VBD stopped_VBN by_IN addition_NN of_IN SDS_NNP sample_NN buffer_NN ,_,
          and_CC reaction_NN products_NNS were_VBD separated_VBN by_IN SDS_NNP gel_NN
          electrophoresis_NNS and_CC detected_VBN by_IN autoradiography_NN ._.
        
      
      
        Abbreviations_NNP
        SCF_NNP =_SYM SKP_NNP 1_CD /_NN Cullin_NNP /_NN F-_NNP box_NN protein_NN complex_JJ
        UBC_NNP =_SYM Ubiquitin_NNP conjugating_VBG enzyme_NN
        MIB_NNP =_SYM Mibolerone_NNP
        (_( 7_CD α-_NN 17_CD α-dimethyl-_JJ 19_CD -_: nortestosterone_NN )_)
        SKP_NNP 2_CD =_SYM S_NNP phase_NN kinase_NN associated_VBN protein_NN 2_CD
        CDK_NNP 2_CD =_SYM cyclin-dependent_JJ kinase_NN 2_CD
      
      
        Authors_NNP '_'' contributions_NNS
        All_DT experiments_NNS reported_VBD in_IN this_DT study_NN were_VBD performed_VBN by_IN
        L-F_NNP ._. L_NNP ._. with_IN the_DT following_JJ exceptions_NNS :_: H_NNP ._. S_NNP ._. prepared_VBD the_DT
        SKP_NNP 2_CD -_: ΔF_NN mutant_JJ ,_, SKP_NNP 2_CD adenoviruses_NNS ,_, and_CC provided_VBD initial_JJ
        evidence_NN for_IN p_NN 27_CD upregulation_NN by_IN MIB_NNP ._. D_NNP ._. A_DT ._. W_NNP ._. performed_VBD the_DT
        experiments_NNS shown_VBN in_IN Fig_NNP ._. 5_LS Band_NNP 5_CD C_NNP ,_, conceived_VBD the_DT study_NN ,_,
        and_CC participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ._. All_DT
        authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
